Search filters
Filters
Clear All

Phase

  • 12
  • 39
  • 2
  • 26
  • 1
  • 16
  • 1
  • 251
  • 352
  • 262
  • 4
  • 25
  • 323

Found 352 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 27424 Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel

99 years or below
All genders
The goal of this study is to provide access to axicabtagene ciloleucel for patients diagnosed with a disease approved for treatment with axicabtagene ciloleucel, that is otherwise out of specification for commercial release.
Learn More

UPCC 22424: A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants with High-Risk Multiple Myeloma

99 years or below
All genders
The purpose of this study is to see if using talquetamab either before or after ciltacabtagene autoleucel is safe and useful for treating patients with multiple myeloma. We would like to rely on Sterling IRB as the IRB of record for this study.
Learn More

UPCC 26424: An Analysis of Manufacturing Outcomes with Patient Factors from Multiple Myeloma Patients Prescribed Ciltacabtagene Autoleucel

99 years or below
All genders
The purpose of this study is to learn how participant factors (such as medical history and manufacturing starting material, also known as Apheresis) can predict successful manufacturing of ciltacabtagene autoleucel (Cilta-cel). This information can be used to potentially improve manufacturing processes and treat more patients with Cilta-cel. We would like …
Learn More

UPCC 03524: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural

99 years or below
All genders
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma. We would like to rely on WCG IRB as …
Learn More

UPCC 03424 Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients with Relapsed or Refractory Large B-cell Lymphomas

99 years or below
All genders
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints) and Protocol Section 9.4 (Primary and Secondary Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints) and Protocol Section 9.4 (Primary and Secondary Endpoints).
Learn More

UPCC 28424 Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel

99 years or below
All genders
The goal of this study is to provide access to brexucabtagene autoleucel for patients diagnosed with a disease approved for treatment with brexucabtagene autoleucel, that is otherwise out of specification for commercial release. We would like to rely on Advarra IRB as the IRB of record for this study.
Learn More

UPCC 32424: An Open-Label, Expanded Access Program of Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease in Participants Who Have Received at Least 2 Lines of Systemic Therapy

99 years or below
All genders
To provide axatilimab through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for axatilimab in the treatment of GVHD. We would like to rely on Advarra as the …
Learn More

MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials

99 years or below
All genders
Evaluate the feasibility of MATCHBox receiving and organizing all data needed for assignment to a myeloMATCH clinical trial or Tier Advancement Pathway (TAP) within 72 hours of MDNet receipt of all required specimens for initial therapy and within 10 days for subsequent therapy.
Learn More

UPCC 16524: A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of Intratumorally Administered INT230-6 (SHAO, vinblastine, cisplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, Inoperable, or

99 years or below
All genders
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless …
Learn More

UPCC 36424 Phase 2, Open-Label, Multicenter, Dose-Optimization Study of the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Volasertib in Combination With Decitabine in Patients With Relapsed/Refractory Acute Myeloid Leukemia

99 years or below
All genders
The purpose of this study is to test the safety and tolerability of volasertib combined with decitabine in participants with relapsed/refractory acute myeloid leukemia. We would like to rely on Advarra IRB as the IRB of record for this study.
Learn More
321 - 330 of 352